A Study to Evaluate Subcutaneous Durvalumab in Patients with Non-Small Cell Lung Cancer and Small Cell Lung Cancer

Trial Identifier:	D9072C00001
Sponsor:	AstraZeneca
Start Date:	June 2021
Primary Completion Date:	August 2023
Study Completion Date:	August 2023
Condition:	Lung Cancer

Available Languages

For questions about your Trial Results Summary, please see Sponsor contact section within your Trial Results Summary.

Language	Description
	English Version
	English Translation
	Spanish Translation
	Spanish Translation
	Chinese Translation

Stay informed about new Trial Results Summaries with our email notification service

Trial Locations

Country	Location
ES	Badalona, ES, 08916
ES	Majadahonda, ES, 28222
NZ	Christchurch, NZ, 8011
TW	Taichung, TW, 40705
TW	Taipei City, TW, 11217
TW	Taipei City, TW, 114
US, TX	Houston, TX, US, 77090
US, VA	Fairfax, VA, US, 22031

Pharma Intelligence UK Limited is a company registered in England and Wales with company number 13787459 whose registered office is 3 More London Riverside, London SE1 2AQ.

Copyright © 2025 Pharma Intelligence UK Limited (Citeline), a Norstella company